Intellectual Property Rights MCQs for CLAT PG, Page 3

Correct answer: B. Intellectual property protection should accommodate the incremental and cumulative nature of innovation in certain fields; if exclusive rights were so broad as to prevent use of protected material as a starting point for further innovation (the 'blocking' problem), follow-on innovation would be inhibited; Section 30's research exemption balances the breeder's commercial rights with the need to keep the innovation system dynamic by allowing new breeders to build on existing registered varieties

The researchers' rights exemption in Section 30 of the PPVFR Act reflects the same IP policy rationale as the research exemption in patent law (Section 47 of the Patents Act) and the idea-expression dichotomy in copyright: intellectual property rights must leave sufficient freedom for follow-on creativity and innovation. In plant breeding, new varieties are typically created by crossing existing varieties (including registered commercial varieties) with other material. If breeders required licences to use registered varieties as crossing parents, the cost and complexity of obtaining licences would significantly impede plant breeding research, particularly in public sector institutions and small companies. Section 30's exemption is 'essentially derived variety' licensing only: the exemption allows use for breeding but the resulting variety cannot itself be registered if it is 'essentially derived' from the protected variety without the original breeder's consent - striking the balance between enabling innovation and protecting commercial investment.

Source note: PPVFR Act 2001, Section 30

Correct answer: B. Upov's framework, particularly its 1991 Act, is perceived as insufficiently protective of farmers' rights and traditional farming practices, making it an unsuitable model for India's smallholder-dominated agricultural sector

The passage explicitly states India's reason for not joining UPOV: 'India chose not to join the Union for the Protection of New Varieties of Plants (UPOV)... precisely because UPOV's framework - particularly the 1991 Act - is perceived as insufficiently protective of farmers' rights and traditional farming practices.' UPOV 1991 significantly limited the traditional farmers' privilege to save, exchange, and resell seeds of protected varieties, imposing commercially oriented restrictions that would be extremely disruptive to India's smallholder farming sector where seed-saving is a fundamental practice. The PPVFR Act was designed specifically to grant breeders commercial protection while simultaneously preserving the traditional rights of farming communities - a balance that UPOV 1991 does not strike to India's satisfaction.

Source note: Protection of Plant Varieties and Farmers' Rights Act, 2001

Correct answer: A. Section 3(p) of the Patents Act operates proactively at the application stage, excluding traditional knowledge from patentability so that no patent is granted; Section 41 of the ppvfr Act operates reactively after registration, enabling cancellation of a plant variety registration that inappropriately appropriated community-developed varieties, providing a post-grant remedy rather than a pre-grant exclusion

The passage describes the interplay between the two provisions as creating a 'multi-layered framework.' Section 3(p) of the Patents Act, 1970 operates at the application examination stage: it is an absolute ground for refusing a patent where the claimed invention amounts to traditional knowledge or an aggregation of known properties of traditionally known components. It prevents the grant of patents. Section 41 of the PPVFR Act operates post-registration: it provides a remedy after a plant variety has already been registered, where it can be shown that the registered variety was essentially derived from a community-developed variety without the required acknowledgement and benefit-sharing. Together, the two provisions address bio-piracy at different points in time: Section 3(p) prevents patents from being granted on traditional knowledge, and Section 41 provides a mechanism to revoke plant variety registrations that inappropriately commercialise community agricultural heritage.

Source note: PPVFR Act 2001, Section 41; Patents Act 1970, Section 3(p)

Correct answer: C. The right to save seed is fundamental to the economics of smallholder farming in India: purchasing new commercial seed for every planting season would be prohibitively expensive for subsistence farmers; the seed-saving right under Section 39 ensures that the commercialisation of plant varieties through registration cannot eliminate the traditional farming practice that smallholder farmers have depended on for generations, preserving both their economic viability and agricultural biodiversity

The passage describes the seed-saving right as a response to corporate seed companies' attempts to restrict traditional farming practices through licensing terms. The significance is economic and cultural: smallholder farmers in India have historically saved a portion of each year's harvest as seed for the following season, both as a cost-saving measure and as a means of adapting varieties to local conditions over generations. Commercial licensing models that restrict seed-saving (as some multinational seed companies have implemented through 'shrink-wrap' licensing) would require farmers to purchase new commercial seed every season, fundamentally altering the economics of subsistence farming. Section 39 ensures that the commercialisation of new varieties does not eliminate this practice. However, the passage also notes a limitation: farmers cannot sell saved seed as 'branded seed' of the registered variety - they can save and use it personally or exchange it informally, but cannot commercially market it as the registered variety.

Source note: PPVFR Act 2001, Section 39

Correct answer: D. Government acquisition rights (right of the government to compulsorily purchase seed stocks during food security emergencies)

The passage identifies three specific categories of rights preserved by the PPVFR Act: (1) farmers' rights under Section 39; (2) researchers' rights under Section 30; and (3) community rights under Chapter V. Government acquisition or compulsory purchase rights are not mentioned in the passage as one of the three categories distinct from patent systems. While compulsory licensing in exceptional circumstances exists (analogous to patent compulsory licensing), this is not described as one of the three categories that make the PPVFR Act unique compared with patent systems. The three enumerated categories all represent rights of communities and researchers - not government powers - and their distinctiveness from patent law reflects India's policy of balancing commercial breeders' rights with the rights of those who have historically contributed to agricultural biodiversity.

Source note: PPVFR Act 2001, Sections 30, 39, Chapter V

Correct answer: A. A dedicated sui generis (unique, purpose-built) statutory framework for TCEs that: recognises collective community ownership; does not require a fixed creation date or individual author.

The passage identifies the core problem: conventional IP law's individual-author-fixed-date-limited-term framework is incompatible with TCEs' communal-anonymous-indeterminate-age character. A sui generis system - as India employed for plant variety protection through the PPVFR Act (rather than using the Patents Act) - is the model that can address characteristics that existing IP law cannot accommodate. Such a framework would need to: depart from individual authorship requirements (recognising collective community ownership); abandon fixed creation dates (protecting TCEs regardless of when they came into existence); provide indefinite or perpetually renewable protection rather than a fixed term (since cultural heritage does not stop being culturally significant after sixty years); require prior informed consent for commercial use (addressing the cultural extractivism problem); and establish benefit-sharing obligations (ensuring communities receive a share of commercial proceeds). Several countries in Africa and Latin America have enacted standalone TCE protection laws that provide models for such legislation.

Source note: TCE protection; PPVFR Act analogy

Correct answer: C. A global fashion brand incorporating the distinctive geometric patterns of a specific indigenous tribal community into a mass-produced clothing line marketed internationally, without any acknowledgement of the community, attribution of cultural origin, or sharing of the commercial proceeds with the community whose heritage was the source of the design

The passage defines cultural piracy/extractivism as occurring when 'commercial entities incorporate [TCEs] into products... and sell for profit without attribution or benefit-sharing with the communities whose heritage has been exploited.' The specific examples given are: 'tribal patterns on mass-produced clothing' (the fashion industry), 'sampling of indigenous musical traditions in commercial recordings' (the music industry), and 'traditional healing practices' (the pharmaceutical sector). A global fashion brand commercially exploiting a specific tribal community's geometric patterns without attribution or benefit-sharing is precisely the paradigm case of cultural extractivism. The museum display and academic recording are non-commercial uses that would generally be seen as preservation or education, not exploitation. The fashion blogger scenario lacks commercial exploitation. Only option B involves mass commercial production and sale without attribution or sharing of commercial proceeds.

Source note: TCE protection; fashion industry; cultural piracy

Correct answer: A. TCEs are typically communal (not individually authored), anonymous (no identifiable single creator), and of indeterminate age (not created at a specific moment that could serve as the start of a protection period) - all features that conflict with conventional IP law's requirement for individual authors, specific dates of creation, and fixed terms of protection

The passage identifies three specific characteristics that create the incompatibility: 'TCEs are typically communal, anonymous, and of indeterminate age.' These three features directly conflict with the architecture of conventional IP law. Copyright requires an identifiable individual author and a specific creation date (from which the term - life plus sixty years - is calculated). Patent law requires an identifiable inventor and a specific date of invention. Trade mark law requires an identifiable proprietor. TCEs have none of these: they are the collective creation of communities, their authors are unknown (having accumulated contributions over generations), and their age is uncertain (they may be hundreds of years old). The result is that no individual or community can claim copyright or patent in a TCE under existing law, leaving them legally unprotected and vulnerable to appropriation.

Source note: GI Act 1999; Copyright Act 1957; WIPO IGC; Biological Diversity Act 2002

Correct answer: D. There is a fundamental divergence of interests between developed countries (which are typically net 'importers' of TCEs from the commercial perspective, with large cultural industries that have benefited from freely appropriating traditional knowledge and cultural expressions) and developing and indigenous-nation countries (which seek binding protection as sources of TCEs being commercially exploited); this structural conflict of interest has prevented consensus on a binding instrument

The prolonged negotiation (since 2000) without a binding outcome reflects the structural tension in international IP norm-setting. Developed countries - home to large fashion, music, and pharmaceutical industries that have historically used traditional knowledge and cultural expressions without restriction - have generally resisted binding instruments that would create legal obligations to seek consent or share benefits. Developing countries, particularly from the African Group, Latin America, and Asia (including India), are the primary advocates for binding TCE protection, reflecting their position as sources of the heritage being commercially exploited. This is the same structural tension that characterised the TRIPS negotiations in the 1990s (where developed countries pushed for stronger IP protections and developing countries resisted). The difficulty of reaching consensus reflects the real economic stakes: a binding TCE instrument could require consent and benefit-sharing arrangements that significantly affect the operating model of industries built on freely incorporating traditional designs, music, and knowledge.

Source note: WIPO IGC; international TCE protection

Correct answer: A. The proviso to Section 9(1), which allows descriptive marks to become registrable through acquired distinctiveness (secondary meaning) while the main provision refuses registration to purely descriptive marks, thereby simultaneously protecting commerce and competitive freedom

The passage identifies the balance between two competing interests: protecting traders who have built brands and preventing monopolisation of descriptive language. The mechanism that achieves this dual objective is the combination of Section 9(1) (refusing descriptive marks) and its proviso (allowing descriptive marks to be registered after acquiring distinctiveness through use). The main provision protects the freedom of all traders to use descriptive language by refusing initial registration; the proviso rewards genuine brand-building effort by allowing registration once the mark has earned distinctiveness through investment and use. This is the balance the passage describes. The other options address different aspects of trade mark law and do not capture this specific balance.

Source note: Trade Marks Act 1999, Section 9

Correct answer: A. How the mark would represent itself to the general public in everyday life and common understanding, not its technical or grammatical significance

The passage expressly states, following the Calcutta High Court's reasoning in the Hindusthan Development Corporation case, that the test is not one of grammatical significance. The court held that the mark must be considered 'not in its grammatical significance but as it would represent itself to the public at large' - a practical test assessed from the perspective of ordinary people who encounter the word in daily life. The court applied this test to find that 'Rasoi' (kitchen/cooking) had a direct quality reference when used for cooking oil, as ordinary consumers would associate the word with cooking. Options A, C, and D all suggest technical or quantitative measures that are inconsistent with the passage's emphasis on a practical, consumer-perception test.

Source note: Trade Marks Act 1999, Section 9; M/s Hindusthan Development Corporation Ltd. v. The Deputy Registrar of Trade Marks, AIR 1955 Cal 519

Correct answer: D. Even if a mark appears prima facie registrable, Section 9 imposes absolute grounds for refusal and Section 11 imposes relative grounds for refusal, and the Registrar retains discretion to refuse registration if it is not in the public interest, meaning registration cannot be demanded as of right

The passage characterises trade mark registration as a matter of 'statutory discretion' because the Trade Marks Act, 1999 imposes mandatory grounds for refusal (absolute grounds under Section 9 and relative grounds under Section 11) that constrain and in some cases require refusal of registration. Even where a mark clears the absolute and relative grounds, the Registrar retains a residual discretion to refuse registration in appropriate circumstances. This is distinct from a 'right': if registration were a matter of right, an applicant who satisfied all formal requirements would be entitled to demand registration. The law's structure makes clear that registration is earned, not merely claimed. Option A is incorrect because fees do not determine whether registration is a right. Option C is incorrect because there are appellate remedies. Option D is incorrect as it misrepresents the law.

Source note: Trade Marks Act 1999

Correct answer: B. A descriptive word that would ordinarily be refused registration may become registrable if, through sustained commercial use, it has acquired an additional meaning in the minds of consumers that identifies the applicant as the commercial source, beyond its primary descriptive sense

The passage explains the proviso to Section 9(1) as providing a 'redemptive pathway': a word that is prima facie descriptive (and therefore refused registration under Section 9(1)) may still be registered if it has 'acquired a distinctive character as a result of the use made of it.' The passage further explains this as the doctrine of secondary meaning - 'whereby a word, through sustained commercial use, sheds its primary descriptive sense in the minds of consumers and acquires a secondary, trade-source-identifying meaning associated with the applicant's goods.' The word thus develops a dual meaning: its original descriptive meaning, and a secondary (acquired) meaning that identifies the applicant. Options A, C, and D all misrepresent the doctrine.

Source note: Trade Marks Act 1999, Section 9 proviso

Correct answer: C. Preventing any single trader from monopolising descriptive words that other traders in the same field legitimately need to describe their own goods

The passage uses 'prophylactic mechanism' to describe the preventive function of absolute grounds for refusal: they prevent the monopolisation of descriptive words. The passage specifically states that the law 'functions as a prophylactic mechanism, preventing the monopolisation of descriptive words that other traders in the same field require to describe their goods honestly.' The rationale is that if one trader could monopolise a descriptive word (such as 'sweet' for confectionery, or 'cold' for refrigerators), all other traders in that field would be unable to use ordinary language to describe their goods. This would create an unreasonable competitive advantage. The provision therefore serves the public interest in maintaining a competitive marketplace where descriptive language remains freely available to all traders.

Source note: Trade Marks Act 1999, Section 9

Correct answer: C. Goodwill or reputation attached to the claimant's mark, misrepresentation by the defendant likely to cause confusion, and actual or foreseeable damage to the claimant's goodwill

The passage clearly and expressly sets out the three elements of the passing off trinity: first, the existence of goodwill or reputation attached to the claimant's goods in the mind of the purchasing public; second, a misrepresentation by the defendant likely to lead the public to believe the defendant's goods are those of the claimant or associated with the claimant; and third, actual damage or a reasonably foreseeable risk of damage to the claimant's goodwill. Critically, passing off does not require a registered trade mark (so option A is incorrect) and does not require fraudulent intent (so option D is incorrect). The passage attributes this formulation to the House of Lords in Reckitt and Colman Ltd. v. Borden Inc., which has been consistently followed by Indian courts.

Source note: Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd., (2001) 5 SCC 73; Milmet Oftho Industries v. Allergen Inc., (2004) 12 SCC 624

Correct answer: A. Passing off is available to protect both registered and unregistered marks based on goodwill and misrepresentation, while infringement under the Trade Marks Act, 1999 is a statutory action available only to registered mark owners

The passage establishes that passing off protects a trader's goodwill without reference to registration: the elements are goodwill, misrepresentation, and damage - none of which require a registered trade mark. This implies that passing off is available to owners of both registered and unregistered marks who have established goodwill. Trade mark infringement under the Trade Marks Act, 1999 is a statutory remedy that requires the claimant to own a registered mark; the defendant's use of an identical or confusingly similar mark constitutes infringement regardless of intent. The Milmet Oftho case illustrates passing off protecting a foreign company (Allergen) that had no registered Indian trade mark and no Indian trading presence - the claim succeeded entirely on the basis of trans-border reputation and goodwill. Option A is incorrect: the passage states 'actual damage or a reasonably foreseeable risk of damage,' so actual damage is not always required.

Source note: Passing off doctrine

Correct answer: B. Confusion between drug names can cause risks extending beyond commercial loss to serious harm to human health, including the risk of administering or prescribing incorrect medication with potentially life-threatening consequences

The passage provides an unambiguous explanation for the heightened standard: medicines 'occupy a qualitatively different position from ordinary consumer goods' because 'confusion between drug names carries risks that extend well beyond commercial loss to encompass serious harm to human health.' A mistake in identifying a drug name could lead to administration of an entirely inappropriate medication 'with potentially life-threatening consequences.' It is this public health dimension - the possibility of harm to patients - that justifies applying stricter scrutiny in pharmaceutical passing off cases. The court's approach in Cadila therefore reflects the principle that legal protections should be calibrated to the stakes involved, with matters involving public health receiving heightened protection.

Source note: Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd., (2001) 5 SCC 73

Correct answer: C. The standard for assessing likelihood of confusion in passing off is calibrated to the least careful member of the class of likely purchasers; if the class includes persons who may rely on oral communication rather than written labels, the potential for confusion from phonetically similar drug names is heightened, justifying greater protection

The passage's reference to 'semi-literate, illiterate, and elderly patients who may rely entirely on oral communication rather than reading the label' is significant for the legal standard of confusion. In assessing likelihood of confusion in a passing off action, courts look at the realistic purchasing experience of the actual consumers of the goods. If a drug is purchased by patients who cannot read labels and rely entirely on hearing the name spoken, then phonetically similar names (such as two brands whose names sound alike when spoken) present a particularly severe risk of confusion. The court therefore applies its assessment to the least informed and least careful segment of the class of purchasers, not just to well-educated, careful consumers. This consumer-calibrated standard is an important feature of pharmaceutical trade mark law that the Supreme Court emphasised in Cadila.

Source note: Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd., (2001) 5 SCC 73

Correct answer: D. The international character of the pharmaceutical industry and the access of the professional community to global medical literature mean that internationally known drug brand names acquire a functional reputation in India even without domestic trading

The passage explains the Milmet Oftho holding in terms of the specific characteristics of the pharmaceutical industry: 'the international character of the pharmaceutical industry and the professional community's access to global medical literature' mean that doctors and pharmacists in India are aware of internationally known drug names through professional journals and literature. This awareness creates a functional reputation for the mark in India even without direct commercial activity in India. The passage does not cite the Paris Convention as the basis; the decision rests on the trans-border reputation doctrine, which is a common law development. Option C misrepresents the Trade Marks Act. Option D is too broad and would apply to all industries, which is not the court's reasoning.

Source note: Milmet Oftho Industries v. Allergen Inc., (2004) 12 SCC 624

Correct answer: D. Section 27 voids agreements in restraint of trade, creating tension with non-compete clauses; Indian courts have generally enforced narrow, time-limited confidentiality obligations focused on protecting genuine trade secrets, while holding overly broad non-compete clauses (which prevent former employees from working in any competing capacity) to be void as unlawful restraints of trade

The passage identifies the tension precisely: 'Section 27 of the Indian Contract Act, 1872, which voids agreements in restraint of trade, creates a tension with non-compete agreements that employers use to protect trade secrets after employment ends.' The resolution: 'Indian courts have generally been more willing to enforce narrowly framed confidentiality obligations than broad non-compete clauses, which are frequently held to be void as unlawful restraints of trade.' The distinction courts draw is between a confidentiality clause (protecting specific information - acceptable) and a non-compete clause (preventing the former employee from working in the industry at all - potentially void). The former is a reasonable protection of trade secrets; the latter may be an unreasonable restraint on the employee's right to earn a living. Option D overstates the consequence of Section 27; it does not make all such protection impossible.

Source note: Indian Contract Act 1872, Section 27

Correct answer: A. Trade secrets require neither registration nor disclosure as a condition of protection and can theoretically be maintained in perpetuity, in contrast to patents which require full public disclosure in exchange for a time-limited monopoly

The passage states: 'they are the only major form of IP that requires neither registration nor disclosure as a condition of protection, and they can theoretically be maintained in perpetuity.' The passage then contrasts trade secrets with patents: 'While patents require full public disclosure in exchange for a time-limited monopoly, trade secrets protect commercially valuable information precisely by keeping it confidential - the antithesis of the patent bargain.' The Coca-Cola formula example illustrates perpetual protection through secrecy. These two features - no disclosure, potentially infinite duration - make trade secrets structurally distinct from all other IP forms. Option D restates the requirement for secrecy but characterises it as a restriction rather than the defining feature of the protection. Options A and C are not mentioned in the passage.

Source note: TRIPS Agreement, Article 39; Indian Contract Act 1872, Section 27

Correct answer: A. A company might choose trade secret protection when: the innovation can be kept secret reliably (no reverse engineering); the intended protection period exceeds the patent term.

The passage contrasts the patent bargain (full public disclosure in exchange for a time-limited monopoly) with trade secret protection (indefinite protection through confidentiality, with no disclosure requirement). The Coca-Cola example illustrates the trade-off: by maintaining the formula as a secret rather than patenting it, the company has achieved protection for over a century, far exceeding the twenty-year patent term. A rational company would choose trade secrets over patents when: (a) reliable secrecy is achievable; (b) perpetual protection is more valuable than a time-limited patent monopoly; and (c) the company does not want to disclose the technology in a way that allows competitors to benefit from the public disclosure after patent expiry. Option C is incorrect: trade secrets provide no protection against independent discovery, unlike patents. Option D misunderstands the trade secret - the Coca-Cola formula is presumably novel but was chosen for trade secret rather than patent protection strategically.

Source note: TRIPS Agreement, Article 39; Patents Act 1970

Correct answer: B. Through the common law of breach of confidence, express contractual provisions such as non-disclosure agreements, and limited provisions under the Information Technology Act, 2000 for digital information

The passage directly answers this question: 'Protection in India derives from the common law of breach of confidence, express contractual provisions (non-disclosure agreements), and, for digital information, limited provisions under the Information Technology Act, 2000.' These three mechanisms constitute India's current regime for trade secret protection in the absence of dedicated legislation. The passage notes the practical challenges this creates: 'the common law of breach of confidence - developed through equity jurisprudence... provides protection but lacks the procedural clarity and statutory remedies of dedicated legislation.' Options A, C, and D introduce mechanisms not mentioned in the passage.

Source note: Indian Contract Act 1872; IT Act 2000

Correct answer: C. The information must be secret (not generally known or readily ascertainable); it must have commercial value because of its secrecy.

The passage explicitly states the three TRIPS requirements for trade secret protection: 'The three requirements for protection are that the information must: be secret (not generally known or readily ascertainable to persons who normally deal with information of that kind); have commercial value because of its secrecy; and be subject to reasonable steps taken by its holder to maintain its secrecy.' These three requirements - secrecy, commercial value from secrecy, and reasonable protective steps - directly track Article 39(2) of TRIPS. Option A describes registration requirements that do not apply to trade secrets. Option C describes patent requirements. Option D describes contractual formalities not required by TRIPS.

Source note: TRIPS Agreement, Article 39

Correct answer: C. India's obligations under the TRIPS Agreement to introduce product patent protection for pharmaceutical and agricultural chemical products, which India had deferred through transitional provisions until 2005

The passage states that 'India implemented its TRIPS obligations progressively, with the landmark 2005 amendment to the Patents Act, 1970 introducing product patents for pharmaceutical and agricultural chemicals.' TRIPS Article 65 permitted developing countries a general transition period of five years (until 2000) and Article 65(4) provided an additional five years (until 2005) for product patent protection in pharmaceutical and agricultural chemical sectors - provided the country had not previously granted such protection. India had maintained a process-only patent system for pharmaceuticals since the 1970 Act, enabling its generic industry to produce affordable versions of patented drugs through alternative processes. The 2005 amendment fulfilled the TRIPS obligation by introducing product patent protection, directly affecting the generic sector. This change prompted the landmark Novartis v. Union of India litigation about Section 3(d)'s patentability standards.

Source note: TRIPS Agreement 1994; Patents Act 1970 (2005 Amendment); Doha Declaration 2001

Correct answer: C. If TRIPS was a bargain, then the IP standards it imposes must be understood in the context of the development expectations that motivated developing countries to accept them; if developed countries have not fully delivered on market access commitments, the contractual logic of the bargain supports developing countries' use of TRIPS flexibilities to preserve their domestic policy space and development interests - TRIPS should not be read as imposing maximum IP standards but as establishing a floor, not a ceiling

The framing of TRIPS as a 'bargain' - in which developing countries accepted stronger IP obligations in exchange for market access benefits - has important interpretive implications. If TRIPS was a reciprocal bargain, then the IP obligations accepted by developing countries were conditioned on the delivery of market access benefits. Critics argue that developed countries have not fully delivered on agricultural market access commitments (the Doha Round agricultural negotiations collapsed), yet continue to pressure developing countries for TRIPS-plus IP standards beyond those initially agreed. The bargain framing also supports the position that TRIPS's minimum standards create a floor (countries must meet at least these standards) rather than a ceiling (countries are not prevented from taking more flexible approaches consistent with TRIPS); countries can use TRIPS flexibilities freely without violating the spirit of the agreement. This interpretation is supported by the Doha Declaration's affirmation that TRIPS should be implemented 'in a manner supportive of WTO members' right to protect public health' and consistent with their 'right to use... the flexibilities provided in the TRIPS Agreement.'

Source note: TRIPS Agreement history; Uruguay Round

Correct answer: B. Data exclusivity prevents regulatory authorities (such as the cdsco in India) from relying on the originator's undisclosed clinical trial data to grant marketing approval to a generic version of a drug for a defined period (typically 5-10 years), even after the originator's patent has expired; this effectively extends market exclusivity beyond the patent term because generics cannot obtain regulatory approval without repeating expensive clinical trials

Data exclusivity is a protection for clinical trial data that pharmaceutical companies generate to obtain regulatory marketing approval. TRIPS Article 39.3 requires protection of undisclosed test data against 'unfair commercial use,' but does not specifically require that regulatory authorities refuse to rely on originator data when approving generic versions (so-called 'data linkage' or 'data exclusivity'). The TRIPS-plus version of data exclusivity - as sought by the US and EU in FTA negotiations - goes further: it prevents the drug regulatory authority from granting marketing approval to a generic during a defined exclusivity period (typically five to ten years), by prohibiting reliance on the originator's data. Since generic manufacturers cannot afford to replicate all clinical trials, this effectively blocks generic market entry for the exclusivity period even after the patent expires, extending market exclusivity beyond the patent term. India has not implemented data exclusivity in this TRIPS-plus sense, a position the passage implicitly supports as preserving 'policy space' for public health.

Source note: TRIPS-plus; FTA negotiations